GlassScriptPhysician profile
Richard A Yonker
NPI 1467439471
$10,417.84
in general payments reported to CMS, 2019-2025
24 companies · $19.88 in 2025
The $19.88 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,203 · 2020: $2,021 · 2021: $1,056 · 2022: $1,585 · 2023: $1,264 · 2024: $1,269 · 2025: $19.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.03 | 2019-2024 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,500.65 | 2019-2025 | |
| Amgen INC. | $1,438.16 | 2019-2024 | Evenity, Krystexxa, Tavneos |
| Janssen Biotech, INC. | $1,186.35 | 2019-2023 | Tremfya |
| Glaxosmithkline, LLC. | $870.04 | 2019-2024 | Benlysta |
| Pfizer INC. | $791.01 | 2019-2024 | |
| Ucb, INC. | $636.46 | 2019-2024 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $570.87 | 2021-2024 | |
| Lilly USA, LLC | $244.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $236.57 | 2019-2024 | Orencia |
| Janssen Scientific Affairs, LLC | $231.82 | 2020-2024 | Tremfya |
| Genentech USA, INC. | $175.79 | 2019-2020 | |
| Radius Health, INC. | $161.05 | 2019-2022 | |
| Johnson & Johnson Health Care Systems INC. | $156.49 | 2019 | |
| Boston Scientific Corporation | $145.17 | 2024 | Intracept |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $135.65 | 2020-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $111.76 | 2022 | |
| Pacira Therapeutics, INC. | $87.10 | 2019 | |
| Celgene Corporation | $63.63 | 2019 | |
| Medtronic USA, INC. | $62.94 | 2019 | |
| Sobi, INC | $35.70 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.69 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.39 | 2019 | |
| Fidia Pharma USA INC. | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Yonker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.